James Calder
Can Early Remission Become the New Standard in Type 2 Diabetes?
Discover how early remission could redefine type 2 diabetes care, shifting from symptom management to potential disease reversal.
From ‘Patients’ to ‘Consumers’: Is Pharma Finally Ready for the Retail Healthcare Revolution?
"Explore how the Retail Healthcare Revolution is transforming patients into consumers, pushing pharma to adapt or risk obsolescence."
The Hidden Cardiovascular Risks in Type 2 Diabetes: What Every Provider Should Watch For
Explore the hidden cardiovascular risks in type 2 diabetes and learn essential strategies for healthcare providers to improve patient outcomes.
Global Trade Wars and Drug Pricing: The Hidden Threat to Pharma Marketing
Global trade wars challenge pharma marketing by reshaping drug pricing strategies, demanding adaptability and regional focus to mitigate threats.
AI Predicts Diabetes Complications Years in Advance—Here’s How
AI predicts diabetes complications years ahead, revolutionizing care with early interventions and personalized treatments for better outcomes.
From TikTok to Threads: Where Should Pharma Place Its Next Digital Bet?
Discover where pharma should invest digitally: TikTok's reach vs. Threads' community. Which platform aligns with your pharma goals?
Why 40% of Newly Diagnosed Type 2 Diabetes Patients Stop Their Medications Within a...
Discover why 40% of newly diagnosed Type 2 diabetes patients stop medications within a year and explore strategies to improve adherence and outcomes.